Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

NiKem Research and Chiesi Farmaceutici Extend Research Collaboration

September 6, 2011 12:01 pm | News | Comments

Chiesi Farmaceutici and NiKem Research announced details of their extended research collaboration within the respiratory therapeutic area.


AM-Pharma Appoints New CEO

September 6, 2011 11:57 am | News | Comments

AM-Pharma B.V. appointed Erik van den Berg, previously vice president of business development as CEO of the company.


Gilead Amends Study for Ongoing Hepatitis C Trials

September 6, 2011 11:51 am | News | Comments

Gilead Sciences, Inc. announced that, in consultation with the U.S. Food and Drug Administration (FDA), they will amend the design of ongoing clinical trials to discontinue a dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.


Scientists Establish Class of Anti-Diabetic Compound

September 6, 2011 11:46 am | News | Comments

In a joint study, scientists from The Scripps Research Institute and Harvard University’s Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch.


Bacteria Sheds Light on Drug Targets

September 6, 2011 11:40 am | News | Comments

Cancer Research UK scientists have purified a protein found in bacteria that could reveal new drug targets for inherited breast and ovarian cancers , plus other cancers linked to DNA repair faults.


IRCI Camera

September 6, 2011 11:37 am | Product Releases | Comments

Harvard Apparatus’ IRCI allows you to visualize events that are difficult to see in the visible light spectrum such as physiological and metabolic changes in live tissue; levels of hydration and vascularization in tissue and organs; contrast of physical features with no or poor visible contrast and an application of therapeutic agents through injection or aerosol and perfusion paths in organs and microfluidic chips.


Cryopreserved Human Monocytes and CD4+ T-Cells

September 6, 2011 11:32 am | Product Releases | Comments

SeraCare Life Sciences’s Cryo-M Human Monocytes and Cryo-T4 Human CD4+ T-Cells allow investigators to access cryopreserved primary cells with high purity and greater than 90% viability.

Sample Protection Freezer

September 6, 2011 11:07 am | Product Releases | Comments

Thermo Fisher Scientific Inc.’s Revco UxF Series ultra-low temperature (ULT) freezers provide sample protection, while maintaining standards in energy efficiency and capacity per footprint.


Cell-Based Screening

September 6, 2011 11:01 am | Product Releases | Comments

TTP LabTech’s Acumen eX3 system for cell-based screening collects and analyses over 40 images/second, covering every cell in the entire well area, without having to use lower resolution.

Expression Vectors

September 6, 2011 8:32 am | Product Releases | Comments

DNA2.0, the leading provider of bioengineering solutions, announced the expansion of the company’s industry-leading family of expression vectors with the introduction of pJexpress Pichia.


Gel System

September 6, 2011 8:24 am | Product Releases | Comments

GE Healthcare’s horizontal Amersham ECL Gel System is designed for protein electrophoresis enabling efficient and reproducible protein separation. The system works with standard protein detection protocols.


Erasmus Uses Roche-Caliper Sequencing Technology

September 6, 2011 8:10 am | News | Comments

The Genetic Laboratory of the Department of Internal Medicine at Erasmus University Medical Centre in Rotterdam has adopted the combined automated target enrichment solution from Roche and Caliper Life Sciences.


Possible Drug Target for PTSD

September 6, 2011 7:57 am | News | Comments

A team of researchers has identified a promising therapeutic target in the brain that could lead to the treatment of post-traumatic stress disorder. This is the first evidence of a potential drug target for the condition.


Nasal hGH As Effective As Injection

September 6, 2011 7:52 am | News | Comments

Clinical data from Critical Pharmaceuticals' ongoing Phase 1 program for CP024, a nasal formulation of human growth hormone, has shown that CP024 is able to induce IGF-1 to the same levels as a subcutaneous injection of the marketed product.


Novartis Fights Patent Rejection in Indian Court

September 6, 2011 7:43 am | by Katy Daigle | News | Comments

In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments over whether the government had the right to deny a patent to Novartis AG for its lifesaving cancer treatment Gleevec.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.